MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

MDT

97.97

-0.41%↓

VEEV

301.82

-1.22%↓

A

141.04

+1.79%↑

HQY

92.06

+4.03%↑

PHR.US

23.23

-0.43%↓

Search

Arrowhead Pharmaceuticals Inc

Cerrado

SectorSalud

36.94 1.15

Resumen

Variación precio

24h

Actual

Mínimo

36.02

Máximo

37.24

Métricas clave

By Trading Economics

Ingresos

-547M

-179M

Ventas

-515M

28M

Margen de beneficio

-643.397

Empleados

609

EBITDA

-563M

-166M

Recomendaciones

By TipRanks

Recomendaciones

Comprar

Estimación a 12 meses

-1.48% downside

Dividendos

By Dow Jones

Próximas Ganancias

25 nov 2025

Estadísticas de Mercado

By TradingEconomics

Capitalización de Mercado

2.9B

5.2B

Apertura anterior

35.79

Cierre anterior

36.94

Noticias sobre sentimiento de mercado

By Acuity

57%

43%

334 / 371 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bearish Evidence

Arrowhead Pharmaceuticals Inc Gráfico

El rendimiento pasado no es un indicador fiable de resultados futuros.

Noticias Relacionadas

7 oct 2025, 16:58 UTC

Ganancias

BMW Trims 2025 View, Citing Weaker Performance in China

7 oct 2025, 23:43 UTC

Charlas de Mercado

Nikkei May Trade Rangebound; Takaichi's Policy Steps in Focus -- Market Talk

7 oct 2025, 23:36 UTC

Charlas de Mercado

Gold Edges Higher, Supported by Possible Hedging Demand -- Market Talk

7 oct 2025, 23:19 UTC

Charlas de Mercado

Veem Can Secure More Defense Deals Following Northrop Grumman Win -- Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 22:50 UTC

Charlas de Mercado

RBNZ Should Take the Option of a Bigger Cut -- Market Talk

7 oct 2025, 22:40 UTC

Charlas de Mercado

South32's Alaskan Project Seen Starting Sooner, Worth More After U.S. Deal -- Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

7 oct 2025, 21:56 UTC

Charlas de Mercado

Australia Shares Set to Start Day Roughly Flat -- Market Talk

7 oct 2025, 20:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 20:44 UTC

Acciones populares

Stocks to Watch Tuesday Recap: Oracle, Dell, Trilogy Metals -- WSJ

7 oct 2025, 19:42 UTC

Charlas de Mercado

Treasury Yields Fall as Data Blackout Continues -- Market Talk

7 oct 2025, 19:23 UTC

Adquisiciones, fusiones, absorciones

Private-Equity Stocks Have Gotten Crushed. J.P. Morgan Says This One Is a Buy. -- Barrons.com

7 oct 2025, 19:07 UTC

Charlas de Mercado

Oil Futures Settle Mixed With Higher OPEC+ Supply in View -- Market Talk

7 oct 2025, 19:02 UTC

Charlas de Mercado

U.S. Natural Gas Posts Back-to-Back Gains -- Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Tech, Media & Telecom Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

7 oct 2025, 16:20 UTC

Charlas de Mercado

Home Depot Extended Pro Desk Hours Could Drive Sales Growth -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

AMD's OpenAI Deal Resets Competitive Landscape for Chips -- Market Talk

7 oct 2025, 16:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 15:37 UTC

Charlas de Mercado

Markets for Canadian Aluminum Open Up Beyond U.S. -- Market Talk

7 oct 2025, 15:33 UTC

Charlas de Mercado

Gold Rise Tied to Lower Confidence in Dollar Assets -- Market Talk

7 oct 2025, 15:25 UTC

Charlas de Mercado

Canadian Mining Stocks Rally on U.S. Defense Dept. Deal -- Market Talk

7 oct 2025, 15:15 UTC

Charlas de Mercado

Investors Look to Gold, Bitcoin as Traditional Correlations Break Down -- Market Talk

7 oct 2025, 15:04 UTC

Charlas de Mercado

Market Talk Roundup: Latest on U.S. Politics

7 oct 2025, 15:04 UTC

Charlas de Mercado

Canadian Aluminum Exports Squeezed by Tariffs -- Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

Global Forex and Fixed Income Roundup: Market Talk

7 oct 2025, 14:56 UTC

Charlas de Mercado

U.S. Government Shutdown May Impact Release of Canadian Trade Data -- Market Talk

7 oct 2025, 14:52 UTC

Ganancias

These Stocks Are Moving the Most Today: Tesla, AMD, Ford, Dell, IBM, AppLovin, Trilogy Metals, Aehr, and More -- Barrons.com

Comparación entre iguales

Cambio de precio

Arrowhead Pharmaceuticals Inc Esperado

Precio Objetivo

By TipRanks

-1.48% caída

Estimación a 12 meses

Media 36 USD  -1.48%

Máximo 80 USD

Mínimo 12 USD

De acuerdo con 11 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Arrowhead Pharmaceuticals Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Comprar

11 ratings

6

Comprar

5

Mantener

0

Vender

Puntuación técnica

By Trading Central

11.5 / 12.23Soporte y Resistencia

Corto Plazo

Weak Bearish Evidence

Medio plazo

Weak Bearish Evidence

Largo Plazo

Weak Bearish Evidence

Sentimiento

By Acuity

334 / 371 Clasificación en Salud

Noticias sobre sentimiento de mercado

Coyuntura bajista

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por encima de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Arrowhead Pharmaceuticals Inc

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.
help-icon Live chat